Recent large-scale clinical trials have demonstrated that sodium-glucose cotransporter-2 inhibitors and MR antagonists, in addition to renin-angiotensin system inhibitors, are useful in both diabetic and non-diabetic CKD [7,8], and the use of MR antagonists to suppress CKD progression has attracted attention. The gene discussed is NR3C2; the disease is chronic kidney disease.